Literature DB >> 16765489

Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age.

Deepinder Kaur1, Jun Peng, Shankar J Chinta, Subramanian Rajagopalan, Donato A Di Monte, Robert A Cherny, Julie K Andersen.   

Abstract

Iron elevation is well-documented in the Parkinsonian midbrain but its cause and contribution to subsequent neurodegeneration remain unknown. Mice administered iron at doses equivalent to those found in iron-fortified human infant formula during a developmental period equivalent to the first human year of life display progressive midbrain neurodegeneration and enhanced vulnerability to toxic injury. This may have major implications for the impact of neonatal iron intake as a potential risk factor for later development of Parkinson's disease (PD).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16765489     DOI: 10.1016/j.neurobiolaging.2006.04.003

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  58 in total

Review 1.  Industrial toxicants and Parkinson's disease.

Authors:  W Michael Caudle; Thomas S Guillot; Carlos R Lazo; Gary W Miller
Journal:  Neurotoxicology       Date:  2012-01-30       Impact factor: 4.294

2.  Iron-fortified vs low-iron infant formula: developmental outcome at 10 years.

Authors:  Betsy Lozoff; Marcela Castillo; Katy M Clark; Julia B Smith
Journal:  Arch Pediatr Adolesc Med       Date:  2011-11-07

3.  Synergistic effects of environmental risk factors and gene mutations in Parkinson's disease accelerate age-related neurodegeneration.

Authors:  Jun Peng; May Lin Oo; Julie K Andersen
Journal:  J Neurochem       Date:  2010-11-04       Impact factor: 5.372

Review 4.  Genetics of iron regulation and the possible role of iron in Parkinson's disease.

Authors:  Shannon L Rhodes; Beate Ritz
Journal:  Neurobiol Dis       Date:  2008-07-11       Impact factor: 5.996

5.  Pooled analysis of iron-related genes in Parkinson's disease: association with transferrin.

Authors:  Shannon L Rhodes; Daniel D Buchanan; Ismaïl Ahmed; Kent D Taylor; Marie-Anne Loriot; Janet S Sinsheimer; Jeff M Bronstein; Alexis Elbaz; George D Mellick; Jerome I Rotter; Beate Ritz
Journal:  Neurobiol Dis       Date:  2013-10-08       Impact factor: 5.996

6.  Brain mitochondrial iron accumulates in Huntington's disease, mediates mitochondrial dysfunction, and can be removed pharmacologically.

Authors:  Sonal Agrawal; Julia Fox; Baskaran Thyagarajan; Jonathan H Fox
Journal:  Free Radic Biol Med       Date:  2018-04-04       Impact factor: 7.376

7.  Targeting Iron Dyshomeostasis for Treatment of Neurodegenerative Disorders.

Authors:  Niels Bergsland; Eleonora Tavazzi; Ferdinand Schweser; Dejan Jakimovski; Jesper Hagemeier; Michael G Dwyer; Robert Zivadinov
Journal:  CNS Drugs       Date:  2019-11       Impact factor: 5.749

Review 8.  Iron metabolism and its detection through MRI in parkinsonian disorders: a systematic review.

Authors:  Sara Pietracupa; Antonio Martin-Bastida; Paola Piccini
Journal:  Neurol Sci       Date:  2017-09-02       Impact factor: 3.307

9.  Iron supplementation dose for perinatal iron deficiency differentially alters the neurochemistry of the frontal cortex and hippocampus in adult rats.

Authors:  Raghavendra Rao; Ivan Tkac; Erica L Unger; Kathleen Ennis; Amy Hurst; Timothy Schallert; James Connor; Barbara Felt; Michael K Georgieff
Journal:  Pediatr Res       Date:  2012-10-24       Impact factor: 3.756

Review 10.  Alzheimer's disease as homeostatic responses to age-related myelin breakdown.

Authors:  George Bartzokis
Journal:  Neurobiol Aging       Date:  2009-09-22       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.